Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response

Background: Despite some recent advances, pancreatic ductal adenocarcinoma (PDAC) remains a growing oncological challenge. New drugs capable of targeting more than one oncogenic pathway may be one way to improve patient outcomes. This study characterizes the effectiveness of Metavert a first-in-clas...

Full description

Bibliographic Details

Published in:	Translational Oncology
Main Authors:	Jingyu An, Roma Kurilov, Teresa Peccerella, Frank Bergmann, Mouad Edderkaoui, Adrian Lim, Xu Zhou, Katrin Pfütze, Angela Schulz, Stephan Wolf, Kai Hu, Christoph Springfeld, Sadaf S. Mughal, Lenart Zezlina, Franco Fortunato, Georg Beyer, Julia Mayerle, Susanne Roth, Johannes Hulkkonen, Daniela Merz, Shigenori Ei, Arianeb Mehrabi, Martin Loos, Mohammed Al-Saeedi, Christoph W. Michalski, Markus W. Büchler, Thilo Hackert, Benedikt Brors, Stephen J. Pandol, Peter Bailey, John P. Neoptolemos
Format:	Article
Language:	English
Published:	Elsevier 2024-11-01
Subjects:	Pancreatic cancer Apoptosis Autophagy Molecular subtypes GSK3-β Histone deacetylases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324002365